Long GV, Schachter J, Ribas A, et al. 4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006. ASCO 2018. J Clin Oncol. 2018;36 (suppl; abstr 9503).
PROM’s bij adjuvant dabrafenib + trametinib voor gereseceerd hoogrisicomelanoom met BRAF-mutatie
jun 2019 | Dermato-oncologie